Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment

References

• Averin A, Silvia A, Lamerato L, et al. Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice. Support Care Cancer. 2021;29(4):2179–2186.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network [Internet]. NCCN clinical practice guidelines in oncology. Hematopoietic growth factors. Plymouth (PA): NCCN; 2020; [cited 2020 Dec 28]. Available from: www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf
   Google Scholar
• Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013;24(10):2475–2484.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Reiner M, Morrow PK, et al. The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy. Ann Oncol. 2015;26(7):1452–1458.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Yau L, Nakov R, et al. Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support. Ann Oncol. 2018;29(9):1903–1910.
   PubMed Web of Science ®Google Scholar
• Cerchione C, De Renzo A, Di Perna M, et al. Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience. Support Care Cancer. 2017;25(3):839–845.
   PubMed Web of Science ®Google Scholar
• Cerchione C, De Renzo A, Nappi D, et al. Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies-bendamustine and G-CSF support. Support Care Cancer. 2019;27(5):1587–1588.
   PubMed Web of Science ®Google Scholar
• Kubo K, Miyazaki Y, Murayama T, et al. A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma. Br J Haematol. 2016;174(4):563–570.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network [Internet]. NCCN clinical practice guidelines in oncology. Hematopoietic growth factors short-term recommendations specific to issues with COVID-19 (SARS-CoV-2). Plymouth (PA): NCCN; 2020; [cited 2020 Dec 28]. Available from: www.nccn.org/covid-19/pdf/HGF_COVID-19.pdf.
   Google Scholar
• Gascón P, Aapro M, Ludwig H, et al. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). Support Care Cancer. 2016;24(2):911–925.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Gascón P, Bokemeyer C, et al. Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated “same-day” (< 24 h), “per-guidelines” (24–72 h), and “late” (> 72 h): findings from the MONITOR-GCSF study. Support Care Cancer. 2019;27(6):2301–2312.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration supplemental approval letter of Neulasta® Onpro®; [cited 2021 January 14]. Available from: www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/125031Orig1s170,s179,s181ltr.pdf.
   Google Scholar
• Mahler LJ, DiBlasi R, Perez A, et al. On-body injector: an administration device for pegfilgrastim. Clin J Oncol Nurs. 2017;21(1):121–122.
   PubMed Web of Science ®Google Scholar
• Joshi RS, Egbuna OI, Cairns AS, et al. Performance of the pegfilgrastim on-body injector as studied with placebo buffer in healthy volunteers. Curr Med Res Opin. 2017;33(2):379–384.
   PubMed Web of Science ®Google Scholar
• Stuessy P, Sanchez FA, Schober M. Retrospective review of pegfilgrastim on-body injector delivery rates in a large health system [abstract e18273. J Clin Oncol. 2017;35(15_suppl):e18273–e18273.
   Web of Science ®Google Scholar
• Townley C, Porter C, McMullen N. Comparing grade 4 neutropenia associated with pegfilgrastim administered via the Onpro device versus manual injection with a prefilled syringe. J Hematol Oncol Pharm. 2018;8(3):3397.
   Google Scholar
• US Food and Drug Administration [Internet]. 2018. FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment; [cited 2020 December 6]. Available from: www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-neulasta-help-reduce-risk-infection-during-cancer-treatment.
   Google Scholar
• Waller CF, Ranganna GM, Pennella EJ, et al. Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia. Ann Hematol. 2019;98(5):1217–1224.
   PubMed Web of Science ®Google Scholar
• McBride A, Krendyukov A, Mathieson N, et al. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma. J Med Econ. 2020;23(1):28–36.
   PubMed Web of Science ®Google Scholar
• MacDonald K, McBride A, Alrawashdh N, et al. Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv. J Med Econ. 2020;23(12):1466–1476.
   PubMed Web of Science ®Google Scholar
• McBride A, Balu S, Campbell K, et al. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. Future Oncol. 2017;13(25):2285–2295.
   PubMed Web of Science ®Google Scholar
• McBride A, Campbell K, Bikkina M, et al. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ. 2017;20(10):1083–1093.
   PubMed Web of Science ®Google Scholar
• Sun D, Andayani TM, Altyar A, et al. Potential cost-savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study. Clin Ther. 2015;37(4):842–857.
   PubMed Web of Science ®Google Scholar
• McBride A, Wang W, Campbell K, et al. Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim. J Med Econ. 2020;23(8):856–863.
   PubMed Web of Science ®Google Scholar
• Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract. 2012;18(2):171–179.
   PubMedGoogle Scholar
• Chrischilles E, Delgado DJ, Stolshek BS, et al. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin’s lymphoma. Cancer Control. 2002;9(3):203–211.
   PubMedGoogle Scholar
• Centers for Medicare and Medicaid Services [Internet]. 2020 ASP drug pricing files: ASP drug pricing files July 2020. Woodlawn (MD): CMMS; 2020; [cited 2020 June 3]. Available from: www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2020-asp-drug-pricing-files.
   Google Scholar
• Centers for Medicare and Medicaid Services [Internet]. CMS-1717-FC Medicare Program: Changes to Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs, Addendum B.-Final OPPS Payment by HCPCS Code for CY. Woodlawn (MD): CMMS; 2020; [cited 2020 June 3]. Available from: www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices-Items/CMS-1717-FC.
   Google Scholar
• Tai E, Guy GP, Dunbar A, et al. Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract. 2017;13(6):e552–e561.
   PubMed Web of Science ®Google Scholar
• Official Data Foundation. Medical Care Inflation Calculator; [cited 2020 June 3]. Available from: www.officialdata.org/Medical-care/price-inflation/2012-to-2020?amount=25676.
   Google Scholar